CliffBio
biologic

Egrifta SV

tesamorelin

Loss of exclusivityNovember 2023projected — 12-year biologic exclusivity estimate
CompanyTheratechnologies →See this company's full patent-cliff portfolio

Drug detail

Brand nameEgrifta SV
Active ingredienttesamorelin
Strength2MG
Dosage formFor Injection
RouteSubcutaneous
ModalityBiologic
FDA approvalNovember 2011
Marketing statusRx

More from Theratechnologies

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Egrifta SV patent cliff — loss of exclusivity November 2023 | CliffBio